ZA200103320B - Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-phenylpiperidin-1-YL)-1-propanol. - Google Patents

Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-phenylpiperidin-1-YL)-1-propanol.

Info

Publication number
ZA200103320B
ZA200103320B ZA200103320A ZA200103320A ZA200103320B ZA 200103320 B ZA200103320 B ZA 200103320B ZA 200103320 A ZA200103320 A ZA 200103320A ZA 200103320 A ZA200103320 A ZA 200103320A ZA 200103320 B ZA200103320 B ZA 200103320B
Authority
ZA
South Africa
Prior art keywords
phenylpiperidin
hydroxyphenyl
propanol
hydroxy
preparation
Prior art date
Application number
ZA200103320A
Other languages
English (en)
Inventor
Rainville Joseph Philip
Sinay Jr Terry Gene
Walinsky Stanley Walter
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200103320B publication Critical patent/ZA200103320B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
ZA200103320A 2000-04-28 2001-04-24 Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-phenylpiperidin-1-YL)-1-propanol. ZA200103320B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20067300P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
ZA200103320B true ZA200103320B (en) 2002-10-24

Family

ID=22742684

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200103320A ZA200103320B (en) 2000-04-28 2001-04-24 Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-phenylpiperidin-1-YL)-1-propanol.

Country Status (27)

Country Link
US (1) US6645986B2 (enExample)
EP (2) EP1151995B1 (enExample)
JP (2) JP3615496B2 (enExample)
KR (1) KR100442718B1 (enExample)
CN (2) CN1210262C (enExample)
AR (1) AR028376A1 (enExample)
AT (1) ATE277014T1 (enExample)
AU (1) AU781436B2 (enExample)
BR (1) BR0101630A (enExample)
CA (1) CA2345582C (enExample)
CZ (1) CZ20011471A3 (enExample)
DE (1) DE60105689T2 (enExample)
DK (1) DK1151995T3 (enExample)
ES (1) ES2227071T3 (enExample)
HK (1) HK1040246B (enExample)
HU (1) HUP0101723A3 (enExample)
ID (1) ID30006A (enExample)
IL (1) IL142705A0 (enExample)
IN (1) IN191027B (enExample)
PL (1) PL347298A1 (enExample)
PT (1) PT1151995E (enExample)
RU (1) RU2203888C2 (enExample)
SI (1) SI1151995T1 (enExample)
TR (1) TR200402696T4 (enExample)
TW (1) TW200505858A (enExample)
YU (1) YU27701A (enExample)
ZA (1) ZA200103320B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001272993B2 (en) * 2000-06-21 2005-03-10 Bioarray Solutions, Ltd. Multianalyte molecular analysis
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
EP2264191A1 (en) * 2003-11-21 2010-12-22 ANP Technologies, Inc. Asymmetrically branched polymer conjugates and microarray assays
US8563329B2 (en) 2005-05-02 2013-10-22 Anp Technologies, Inc. Polymer conjugate enhanced bioassays

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
CZ296236B6 (cs) * 1995-08-11 2006-02-15 Pfizer Inc. Trihydrát methansulfonátu (1S,2S)-1-(4-hydroxyfenyl)-2-(4-hydroxy-4-fenylpiperidin-1-yl)-1-propanolu, farmaceutický prostredek a farmaceutická kombinace s jeho obsahem

Also Published As

Publication number Publication date
CA2345582A1 (en) 2001-10-28
KR20010098960A (ko) 2001-11-08
CN1590373A (zh) 2005-03-09
SI1151995T1 (en) 2004-12-31
ES2227071T3 (es) 2005-04-01
JP2004196823A (ja) 2004-07-15
JP3615496B2 (ja) 2005-02-02
CN1210262C (zh) 2005-07-13
IL142705A0 (en) 2002-03-10
US20020016465A1 (en) 2002-02-07
HK1040246A1 (en) 2002-05-31
AR028376A1 (es) 2003-05-07
TR200402696T4 (tr) 2004-11-22
HUP0101723A2 (hu) 2002-02-28
DE60105689D1 (de) 2004-10-28
AU3889601A (en) 2001-11-01
EP1151995A1 (en) 2001-11-07
CZ20011471A3 (cs) 2002-02-13
PL347298A1 (en) 2001-11-05
US6645986B2 (en) 2003-11-11
EP1151995B1 (en) 2004-09-22
IN191027B (enExample) 2003-09-13
CN1321638A (zh) 2001-11-14
HK1040246B (zh) 2005-10-28
EP1477479A1 (en) 2004-11-17
HU0101723D0 (en) 2001-07-30
ID30006A (id) 2001-11-01
PT1151995E (pt) 2004-11-30
YU27701A (sh) 2003-04-30
DE60105689T2 (de) 2005-11-10
TW200505858A (en) 2005-02-16
CA2345582C (en) 2006-05-30
KR100442718B1 (ko) 2004-08-02
DK1151995T3 (da) 2004-12-13
BR0101630A (pt) 2001-12-04
ATE277014T1 (de) 2004-10-15
AU781436B2 (en) 2005-05-26
HUP0101723A3 (en) 2003-03-28
RU2203888C2 (ru) 2003-05-10
JP2001354651A (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
ZA200202536B (en) Pharmaceutical tramadol salts.
ZA200410015B (en) Pharmaceutical salts.
PL351148A1 (en) 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
GB2336364B (en) Paroxetine salt
ZA966760B (en) (1S,2S)-1-(4-Hydroxyphenyl)-2-(4-Hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate.
ZA993345B (en) Nefazodone dosage form.
IT1317741B1 (it) Metodo per la preparazione di 5-cianoftalide.
AU2003214902A1 (en) Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl.piperidin-1yl)-1-propanol compounds
ZA200105294B (en) Method for producing L-phenylephrine hydrochloride.
ZA200300743B (en) DDS compound and process for the preparation thereof.
IT1319251B1 (it) Metodo per la preparazione di 5-carbossiftalide.
IL157874A0 (en) The citrate salt of 5,8,14,-triazatetracyclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene
MXPA01010700A (es) Acabado ferrofluidico.
IL154458A0 (en) Processes for preparing cilostazol
ZA200103320B (en) Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-phenylpiperidin-1-YL)-1-propanol.
IL163709A0 (en) Fungicidal triazolopyrimidines, methods for producing the same, use thereof for combating harmful fungiand agents containing said substances
HUP0102011A3 (en) Macrolide lhrh antagonists and their use, process for preparing them and pharmaceutical compositions comprising the salds compounds
ZA200103321B (en) Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-phenylpiperidin-1-YL)-1-propanol and intermediates useful therefor.
MXPA03001551A (es) Proceso continuo para preparacion de clorotiazoles pesticidas.
EG23417A (en) Process for the preparation 7 a-methylsteroids.
PL347025A1 (en) Process for preparing 1,5−diaryl−3−substituted pyrazoles
FR2854623B1 (fr) Aquo-oxo chlorure de titane, procede pour sa preparation
MXPA03005165A (es) Nuevo proceso para preparacion de compuestos diaril-4-amino-piperidnilo.
GB2361659B (en) Cutter for forming polygonal holes
HUP0004052A3 (en) Improved process for the preparation of 1-(3-chloro-phenyl)-2-bromo-propane-1-one